Elscint Holding Gamida-Cell, Teva to Develop Commercialize StemEx

Elscint has announced that Teva Pharmaceutical has exercised its option to enter into a joint venture with Gamida-Cell, in which Elscint (through a wholly owned subsidiary) holds 29.2 percent on a fully diluted basis, in order to develop and commercialize StemEx for the treatment of leukemia and lymphoma.

Gamida-Cell is a leader in the expansion of hematopoietic (blood) stem-cell therapeutics in clinical development for cancer and autoimmune diseases, as well as future regenerative cell-based medicines including cardiac and pancreatic repair.